丁苯酞治疗轻度认知功能障碍的临床疗效观察

目的观察丁苯酞治疗轻度认知功能障碍(MCI)的疗效,为寻求治疗MCI的有效药物提供临床证据。方法选择135例2011年10月至2012年10月泰安市中心医院神经内科门诊主诉"记忆障碍"就诊的MCI患者,年龄60~80岁,随机分为胞二磷胆碱对照组(67例)和丁苯酞治疗组(68例),胞二磷胆碱对照组给予胞二磷胆碱及肠溶阿司匹林等药物治疗,而丁苯酞治疗组则在常规治疗的基础上加用丁苯酞软胶囊口服,每次0.2 g,每日3次,以3个月为一疗程。3个月后,治疗组完成59例(失访率13.23%),对照组完成57例(失访率14.93%)。两组患者在治疗前及治疗1个月、3个月后均给予简易精神状态评价量表(MMSE)、蒙特利尔认知评估量表(MoCA)评分,以此评价其临床疗效。组内治疗前后比较采用方差分析,组间不良反应比较采用χ2检验。结果治疗组用药1个月、3个月后的MMSE、MoCA评分均高于同期对照组(t值分别为4.690、10.736、3.259、6.623,均P0.05),且治疗组内3个月后MMSE、MoCA评分高于1个月后(P0.05),而对照组治疗前及治疗后1个月、3个月的两项评分差异无统计学意义(P0.05)。两组患者不良反应发生率差异无统计学意义(P0.05)。结论丁苯酞软胶囊能显著提高MMSE和MoCA评分。丁苯酞软胶囊治疗MCI有效,能显著改善患者的认知功能,提高其生活质量。

Clinical observation of treatment of mild cognitive impairment by butylphthalide

Objective To observe the efficacy of butylphthalide in the treatment of patients with mild cognitive impairment（MCI）.Methods Within 2 years from October2011 to October 2012,135 cases of out-patients with MCI were randomly divided into conventional treatment group （ 67 cases ） and butylphthalide treatment group （ 68 cases） .In general , both groups were given the same basic treatment of citicoline and aspirin;While patients in the butylphthalide treatment group also took butylphthalide soft capsules by 0.2 g,3 times per day, oral administration with a course of 3 months.After 3 months, the treatment group completed 59 cases（loss of follow-up rate was 13.23%）,and the control group completed 57 cases（loss of follow-up rate was 14.93%）.All patients were evaluated before therapy and by1 month and 3 months after therapy with mini-mental state examination（ MMSE ） and Montreal cognitive assessment scale （ MoCA） .To evaluate the clinical efficacy of butylphthalide , the scale scores from both groups of before treatment,1 month and 3 months after treatment were compared with one-way analysis of variance ,χ2 test was used to compare the adverse reactions between the two groups .Results The MMSE and MoCA scores of butylphthalide group at 1 month,3 months after therapy were significantly higher than that of the control group （ t values were 4.690,10.736 ,3.259 ,6.623 , all P＆lt;0.05 ） .Moreover , in the butylphthalide group , MMSE and MoCA scores of the patients after three months therapy was higher than that after one month therapy （ P＆lt;0.05 ） ,while there were no significant differences among the scores of baseline and after treatment in the control group （ P＆gt;0.05） .There was no stastical significance in the incidence of adverse reaction between the＆amp;nbsp;two groups .Conclusion Butylphthalide soft capsule could significantly improve MMSE and MoCA scores of MCI patients.Butylphthalide is effective in the treatment of MCI , which would obviously improve cognitive functi